• A retrospective cohort study was performed to assess the relative risk of upper gastrointestinal (UGI) tract bleeding from two formulations of potassium chloride. Relevant information was obtained from 1980 through 1984 Medicaid billing data from the states of Michigan, Minnesota, Florida, and Ohio. After patients with a history of UGI tract bleeding prior to their first prescription for either of the two potassium chloride preparations under study were excluded, data were analyzed for 28 790 patients (143 512 patient-months) dispensed a microencapsulated formulation exclusively and 76118 patients (560341 patient-months) dispensed a wax-matrix formulation exclusively. The risk of UGI tract bleeding within 30 days after each prescription for the drug of interest was examined. After sampling from the undiseased study subjects and adjusting for multiple potential confounding variables using logistic regression, an odds ratio (95% confidence interval) of 0.67 (0.52 to 0.85) was observed.
(Arch Intern Med 1987;147:954-957)
Strom BL, Carson JL, Schinnar R, et al. Upper Gastrointestinal Tract Bleeding From Oral Potassium Chloride: Comparative Risk From Microencapsulated vs Wax-Matrix Formulations. Arch Intern Med. 1987;147(5):954–957. doi:10.1001/archinte.1987.00370050146025
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: